Implications of Lymph Node Staging on Selection of Adjuvant Therapy for Gastric Cancer in the United States: A Propensity Score-matched Analysis. Issue 2 (February 2016)

• Record Type: Journal Article
• Authors: Datta, Jashodeep; McMillan, Matthew T.; Ecker, Brett L.; Karakousis, Giorgos C.; Mamtani, Ronac; Plastaras, John P.; Giantonio, Bruce J.; Drebin, Jeffrey A.; Dempsey, Daniel T.; Fraker, Douglas L.; Roses, Robert E.
• Is Part Of: Annals of surgery. Volume 263:Issue 2(2016:Feb.)
• Page Start: 298
• Page End: 305
• Publication Date: 2016-02
• Subjects: adjuvant therapy -- chemotherapy -- gastric cancer -- lymph node staging -- node positivity; Surgery -- Periodicals; 617.005
• DOI: 10.1097/SLA.0000000000001360
• Languages: English
• ISSNs: 0003-4932

Abstract

Abstract : Supplemental Digital Content is available in the text Abstract : Objective: To compare the efficacy of adjuvant chemoradiotherapy (CRT) and chemotherapy alone (CA) in gastric adenocarcinoma patients undergoing gastrectomy in the United States (US). Background: A majority of US gastric adenocarcinoma patients are inadequately staged( <15 nodes examined). Despite this, and limited data comparing adjuvant CRT with CA in US patients, national guidelines endorse CA in selected patients undergoing D2 lymphadenectomy. Methods: Resected stage IB-III gastric adenocarcinoma patients receiving adjuvant CRT or CA (n = 3008) were identified in the National Cancer Database (1998–2006). Cox regression identified covariates associated with overall survival (OS). CRT and CA cohorts were matched (3:1) by propensity scores based on the likelihood of receiving CA. OS was compared by Kaplan-Meier estimates. Results: Adjuvant CA was associated with an increased risk of death (HR 1.29, P < 0.001) relative to CRT. Inadequate lymph node staging (LNS) and nodal positivity were strong predictors of risk-adjusted mortality ( P < 0.001). After propensity score-matching, CRT demonstrated superior median OS compared with CA (36.1 vs 28.9 m; P < 0.0001), regardless of stage. CRT was superior to CA in inadequately staged patients (33.1 m vs 24.5 m; P < 0.001); this benefit was less pronounced with increasing nodal examination. CRT improved OS in node-positive disease (29.8 vs 22.2 m; P < 0.001), regardless of LNS adequacy. In node-negative disease, OS did not differ significantly between CRT and CA cohorts; however, node-negative patients undergoing inadequate LNS benefited from CRT. Conclusions: CRT is associated with improved stage-stratified OS compared with CA. Lymph node status and adequacy of surgical staging should influence adjuvant therapy selection in the United States.